Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.
A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).